Fast answer

Retatrutide (LY3437943) is an investigational triple GLP-1/GIP/glucagon receptor agonist. Learn its research profile, how it compares to tirzepatide and how to verify a lot.

Retatrutide (development code LY3437943) is an investigational synthetic peptide that activates three metabolic hormone receptors at once: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. That triple-agonist design has made it one of the most requested tool compounds in contemporary metabolism research. This overview covers its research profile, how it compares with related compounds, and how to source a verifiable lot.

Research status. Retatrutide is investigational and is not approved as a drug. Peplxa supplies lyophilized retatrutide for qualified in-vitro laboratory research only and provides no dosing or clinical guidance.

What is retatrutide?

GLP-1 and GIP are incretin hormones involved in glucose-dependent insulin signaling, appetite regulation and energy balance; glucagon acts primarily on hepatic glucose output and energy expenditure. By engineering a single molecule that engages all three receptors, researchers gained a tool to study combined incretin and glucagon signaling. Retatrutide is the best-known example of a triple agonist, sitting one step beyond dual-agonist compounds in the same research family.

Retatrutide vs tirzepatide vs semaglutide

The three compounds are frequently compared because they sit on the same GLP-1 pathway, but their receptor coverage differs:

CompoundReceptor profileClassStatus
SemaglutideGLP-1 receptorSingle agonistApproved medicines exist (e.g., Ozempic / Wegovy)
TirzepatideGLP-1 + GIP receptorsDual agonistApproved medicines exist (e.g., Mounjaro / Zepbound)
RetatrutideGLP-1 + GIP + glucagon receptorsTriple agonistInvestigational (LY3437943)

The earlier-generation liraglutide is a once-daily GLP-1 receptor agonist that frequently appears in comparative and control work. In a research catalog, these compounds form a logical series for studying receptor coverage from one to three targets.

Why researchers are interested in retatrutide

Quality control: what a retatrutide lot needs

Because retatrutide is a long synthetic peptide, identity confirmation is especially important. A credible lot should include:

Peplxa performs reverse-phase HPLC with UV detection and ESI-MS in positive mode before release, and exposes each record on the Lot Records page. The testing method page documents the workflow. For cell-culture work, request endotoxin information before designing assays.

Handling and storage (laboratory notes)

Retatrutide is supplied as a sealed, freeze-dried powder. Store sealed vials frozen at approximately -20°C and protected from light. When a protocol requires reconstitution, use sterile laboratory diluent, direct it down the inner vial wall and roll gently rather than shaking; refrigerate reconstituted material at 2-8°C and use promptly. Peplxa does not prescribe concentrations or dosing — those are protocol decisions for the researcher.

Sourcing verified retatrutide

Use the checklist in the buying research peptides online guide: inspect the batch COA before purchase, confirm mass-spectrometry identity, and choose a supplier with tracked, discreet shipping and research-only terms. The Peplxa retatrutide product page lists current box specifications and links the lot record; related metabolic tool compounds are grouped under the weight-loss research category.

For in-vitro laboratory research use only. This material is not a drug, food, cosmetic or supplement and has not been evaluated by any regulatory authority. Peplxa does not provide usage, dosing or medical guidance; all handling must follow applicable laboratory safety regulations.

Frequently Asked Questions

What is retatrutide?
Retatrutide (development code LY3437943) is an investigational synthetic peptide designed to activate three metabolic receptors: GLP-1, GIP and glucagon. It is a research compound, not an approved consumer product, and is sold for in-vitro laboratory research only.
How is retatrutide different from tirzepatide?
Tirzepatide is a dual agonist at the GLP-1 and GIP receptors. Retatrutide adds a third target, the glucagon receptor, making it a triple agonist. That additional receptor is the main reason it is studied in energy-expenditure and metabolic research.
Is retatrutide approved?
Retatrutide remains investigational and is not approved as a drug for any indication. Publicly reported phase 2 metabolic programs produced large body-weight reductions, but phase programs and regulatory review are still ongoing. It should not be described or purchased as an approved treatment.
How do I verify the purity of a retatrutide vial?
Match the lot number on the vial to an independent HPLC purity trace and an ESI-MS identity report. The mass spectrum should be consistent with the theoretical molecular mass of retatrutide. Peplxa renders these records by compound on the Lot Records page before purchase.
Do you provide dosing or reconstitution protocols?
No. Peplxa supplies material for in-vitro research and does not provide dosing, administration or medical guidance. General laboratory handling notes (sterile diluent, gentle mixing, frozen lyophilized storage) are provided, not experimental protocols.
What form is retatrutide supplied in?
As a sealed, lyophilized (freeze-dried) powder in glass vials, in boxes of ten with several specification tiers. See the retatrutide product page for the current pack specifications and price.